Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06679270 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Sponsor changed: Amryt Pharma to Chiesi Farmaceutici S.p.A. Site details revised at 1 of 7 sitesv5 Show 1 more changeShow less
    • Site details revised at 1 of 7 sites

    See this version in full on ClinicalTrials.gov ↗

  2. Enrollment target: 15 to 24 Study sites: 6 to 7 · Completion date: Mar 2028 to Dec 2028v4 Show 2 more changesShow less
    • Study sites: 6 to 7
    • Completion date: Mar 2028 to Dec 2028
  3. Study sites: 4 to 6v3
  4. Site details revised at 4 of 4 sitesv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
Trial Details
NCT Number NCT06679270
Lead Sponsor Chiesi Farmaceutici S.p.A.
Conditions Familial Partial Lipodystrophy
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov